Halozyme Therapeutics, Inc.
US ˙ NasdaqGS ˙ US40637H1095

SecurityHALO / Halozyme Therapeutics, Inc.
InstitutionFranklin Resources Inc
Latest Disclosed Ownership1,157,039 shares
Latest Disclosed Value $ 74,779,314
Franklin Resources Inc reports 4.35% decrease in ownership of HALO / Halozyme Therapeutics, Inc.

On May 13, 2026 - Franklin Resources Inc filed a 13F-HR form disclosing ownership of 1,157,039 shares of Halozyme Therapeutics, Inc. (US:HALO) valued at $74,779,431 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 1,209,678 shares of Halozyme Therapeutics, Inc.. This represents a change in shares of -4.35% during the quarter. The current value of the position is $82,763,000 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 1,157,039 -52,639 -4.35 74,779 -8.15 0.0030
2026-02-11 2025-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 1,209,678 133,343 12.39 81,411 3.13 0.0200
2025-11-13 2025-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 1,076,335 202,675 23.20 78,938 73.69 0.0197
2025-08-12 2025-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 873,660 41,128 4.94 45,448 -14.45 0.0120
2025-05-13 2025-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 832,532 72,689 9.57 53,124 46.23 0.0153
2025-02-12 2024-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 759,843 -77,896 -9.30 36,328 -19.62 0.0101
2024-11-27 2024-09-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 837,739 372,066 79.90 45,196 85.37 0.0127
2024-11-12 2024-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 837,739 372,066 45,196 0.0022
2024-08-14 2024-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 465,673 157,969 51.34 24,383 94.79 0.0075
2024-05-13 2024-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 307,704 233,909 316.97 12,517 359.00 0.0040
2024-02-09 2023-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 73,795 59 0.08 2,727 -3.16 0.0013
2023-11-13 2023-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 73,736 -3,361 -4.36 2,817 1.29 0.0014
2023-08-11 2023-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 77,097 -458,942 -85.62 2,781 -86.42 0.0013
2023-05-12 2023-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 536,039 -528,424 -49.64 20,471 -66.20 0.0103
2023-02-10 2022-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 1,064,463 -1,669 -0.16 60,568 43.68 0.0315
2022-11-14 2022-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 1,066,132 377,916 54.91 42,155 39.21 0.0230
2022-08-11 2022-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 688,216 646,475 1,548.78 30,282 1,719.83 0.0150
2022-05-13 2022-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 41,741 -2,191 -4.99 1,664 -5.78 0.0007
2022-02-11 2021-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 43,932 3,287 8.09 1,766 6.84 0.0006
2021-11-12 2021-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 40,645 33,510 469.66 1,653 410.19 0.0006
2021-08-13 2021-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 7,135 495 7.45 324 16.97 0.0001
2021-05-13 2021-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 6,640 472 7.65 277 5.32 0.0001
2021-02-10 2020-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 6,168 6,168 263 0.0001
2017-05-12 2017-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 0 -1,033,808 -100.00 0 -100.00
2017-02-14 2016-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 1,033,808 -1,195,261 -53.62 10,214 -62.07 0.0053
2016-11-14 2016-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 2,229,069 12,140 0.55 26,927 40.74 0.0141
2016-08-11 2016-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 2,216,929 -3,004 -0.14 19,132 -8.99 0.0103
2016-05-10 2016-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 2,219,933 403,645 22.22 21,022 -33.21 0.0112
2016-04-27 2015-12-31 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 1,816,288 9,551 0.53 31,476 29.72 0.0159
2016-02-12 2015-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 1,816,288 31,476
2015-11-10 2015-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 1,806,737 -262,688 -12.69 24,265 -48.07 0.0120
2015-08-12 2015-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 2,069,425 97,179 4.93 46,728 65.91 0.0212
2015-05-14 2015-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 1,972,246 -1,346,454 -40.57 28,164 -33.18 0.0128
2014-05-13 2014-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 3,318,700 579,100 21.14 42,147 2.63 0.0199
2014-02-12 2013-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 2,739,600 -56,000 -2.00 41,067 33.06 0.0201
2013-11-14 2013-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 2,795,600 734,800 35.66 30,863 88.61 0.0164
2013-08-09 2013-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 2,060,800 2,060,800 16,363 0.0093
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.